457 related articles for article (PubMed ID: 31947879)
21. Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?
Zhang Q; Feng Y; Kennedy D
Cell Mol Life Sci; 2017 Mar; 74(5):777-801. PubMed ID: 27622244
[TBL] [Abstract][Full Text] [Related]
22. Implication of cancer stem cells in cancer drug development and drug delivery.
Chow EK
J Lab Autom; 2013 Feb; 18(1):6-11. PubMed ID: 22893634
[TBL] [Abstract][Full Text] [Related]
23. Targeting Cancer Stem Cells Pathways for the Effective Treatment of Cancer.
Dwivedi AR; Thakur A; Kumar V; Skvortsova I; Kumar V
Curr Drug Targets; 2020; 21(3):258-278. PubMed ID: 31433755
[TBL] [Abstract][Full Text] [Related]
24. Cancer stem cells, metabolism, and therapeutic significance.
Yang M; Liu P; Huang P
Tumour Biol; 2016 May; 37(5):5735-42. PubMed ID: 26864589
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
26. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
[TBL] [Abstract][Full Text] [Related]
27. Targeting autophagy in cancer stem cells as an anticancer therapy.
Lei Y; Zhang D; Yu J; Dong H; Zhang J; Yang S
Cancer Lett; 2017 May; 393():33-39. PubMed ID: 28216370
[TBL] [Abstract][Full Text] [Related]
28. At the crossroads of cancer stem cells and targeted therapy resistance.
Wang A; Qu L; Wang L
Cancer Lett; 2017 Jan; 385():87-96. PubMed ID: 27816488
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma.
Kumar D; Gorain M; Kundu G; Kundu GC
Mol Cancer; 2017 Jan; 16(1):7. PubMed ID: 28137308
[TBL] [Abstract][Full Text] [Related]
30. Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective.
Han J; Won M; Kim JH; Jung E; Min K; Jangili P; Kim JS
Chem Soc Rev; 2020 Nov; 49(22):7856-7878. PubMed ID: 32633291
[TBL] [Abstract][Full Text] [Related]
31. Differentiation of Cancer Stem Cells by Using Synthetic Small Molecules: Toward New Therapeutic Strategies against Therapy Resistance.
Maucort C; Di Giorgio A; Azoulay S; Duca M
ChemMedChem; 2021 Jan; 16(1):14-29. PubMed ID: 32803855
[TBL] [Abstract][Full Text] [Related]
32. The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance.
Chen K; Zhang C; Ling S; Wei R; Wang J; Xu X
Cell Death Dis; 2021 Sep; 12(9):835. PubMed ID: 34482364
[TBL] [Abstract][Full Text] [Related]
33. Nigericin selectively targets cancer stem cells in nasopharyngeal carcinoma.
Deng CC; Liang Y; Wu MS; Feng FT; Hu WR; Chen LZ; Feng QS; Bei JX; Zeng YX
Int J Biochem Cell Biol; 2013 Sep; 45(9):1997-2006. PubMed ID: 23831840
[TBL] [Abstract][Full Text] [Related]
34. The bad seed gardener: Deubiquitinases in the cancer stem-cell signaling network and therapeutic resistance.
Qiu GZ; Sun W; Jin MZ; Lin J; Lu PG; Jin WL
Pharmacol Ther; 2017 Apr; 172():127-138. PubMed ID: 27919796
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic antibodies against cancer stem cells: a promising approach.
Sneha S; Nagare RP; Priya SK; Sidhanth C; Pors K; Ganesan TS
Cancer Immunol Immunother; 2017 Nov; 66(11):1383-1398. PubMed ID: 28840297
[TBL] [Abstract][Full Text] [Related]
36. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents.
Zhou HM; Zhang JG; Zhang X; Li Q
Signal Transduct Target Ther; 2021 Feb; 6(1):62. PubMed ID: 33589595
[TBL] [Abstract][Full Text] [Related]
37. Apoptotic and autophagic pathways with relevant small-molecule compounds, in cancer stem cells.
Zhang L; Tong X; Li J; Huang Y; Hu X; Chen Y; Huang J; Wang J; Liu B
Cell Prolif; 2015 Aug; 48(4):385-97. PubMed ID: 26013704
[TBL] [Abstract][Full Text] [Related]
38. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
39. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin.
Saha S; Mukherjee S; Mazumdar M; Manna A; Khan P; Adhikary A; Kajal K; Jana D; Sa G; Mukherjee S; Sarkar DK; Das T
Transl Res; 2015 May; 165(5):558-77. PubMed ID: 25468484
[TBL] [Abstract][Full Text] [Related]
40. New approaches to target cancer stem cells: current scenario.
Insan MB; Jaitak V
Mini Rev Med Chem; 2014 Jan; 14(1):20-34. PubMed ID: 24195662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
